Literature DB >> 9830016

Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation.

W Q Qiu1, D M Walsh, Z Ye, K Vekrellis, J Zhang, M B Podlisny, M R Rosner, A Safavi, L B Hersh, D J Selkoe.   

Abstract

Excessive cerebral accumulation of the 42-residue amyloid beta-protein (Abeta) is an early and invariant step in the pathogenesis of Alzheimer's disease. Many studies have examined the cellular production of Abeta from its membrane-bound precursor, including the role of the presenilin proteins therein, but almost nothing is known about how Abeta is degraded and cleared following its secretion. We previously screened neuronal and nonneuronal cell lines for the production of proteases capable of degrading naturally secreted Abeta under biologically relevant conditions and concentrations. The major such protease identified was a metalloprotease released particularly by a microglial cell line, BV-2. We have now purified and characterized the protease and find that it is indistinguishable from insulin-degrading enzyme (IDE), a thiol metalloendopeptidase that degrades small peptides such as insulin, glucagon, and atrial natriuretic peptide. Degradation of both endogenous and synthetic Abeta at picomolar to nanomolar concentrations was completely inhibited by the competitive IDE substrate, insulin, and by two other IDE inhibitors. Immunodepletion of conditioned medium with an IDE antibody removed its Abeta-degrading activity. IDE was present in BV-2 cytosol, as expected, but was also released into the medium by intact, healthy cells. To confirm the extracellular occurrence of IDE in vivo, we identified intact IDE in human cerebrospinal fluid of both normal and Alzheimer subjects. In addition to its ability to degrade Abeta, IDE activity was unexpectedly found be associated with a time-dependent oligomerization of synthetic Abeta at physiological levels in the conditioned media of cultured cells; this process, which may be initiated by IDE-generated proteolytic fragments of Abeta, was prevented by three different IDE inhibitors. We conclude that a principal protease capable of down-regulating the levels of secreted Abeta extracellularly is IDE.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9830016     DOI: 10.1074/jbc.273.49.32730

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  267 in total

1.  Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling.

Authors:  L Gasparini; G K Gouras; R Wang; R S Gross; M F Beal; P Greengard; H Xu
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

2.  Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization.

Authors:  V Chesneau; K Vekrellis; M R Rosner; D J Selkoe
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

Review 3.  LRP in Alzheimer's disease: friend or foe?

Authors:  P G Ulery; D K Strickland
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

4.  Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis.

Authors:  Kunihiro Uryu; Helmut Laurer; Tracy McIntosh; Domenico Praticò; Daniel Martinez; Susan Leight; Virginia M-Y Lee; John Q Trojanowski
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

Review 5.  Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease.

Authors:  Dennis J Selkoe
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 6.  The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

7.  Potential efficacy of Lactobacillus casei IBRC_M10711 on expression and activity of insulin degrading enzyme but not insulin degradation.

Authors:  Nadia Neyazi; Taiebeh Mohammadi Farsani; Zahra Nouri; Mohammad Hossein Ghahremani; Mohammad Reza Khorramizadeh; Roksana Tajerian; Elahe Motevaseli
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-08-29       Impact factor: 2.416

8.  A capillary electrophoresis method for evaluation of Abeta proteolysis in vitro.

Authors:  Benjamin J Alper; Walter K Schmidt
Journal:  J Neurosci Methods       Date:  2008-11-21       Impact factor: 2.390

9.  CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  Hippocampus       Date:  2018-02-12       Impact factor: 3.899

Review 10.  Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.